IBCN 2019: Immunological Tumor Microenvironment in Patients with Muscle Invasive Bladder Cancer Treated with Radical Cystectomy

Aarhus, Denmark (UroToday.com) Veronika Weyerer from the Institute of Pathology at University Hospital Erlangen presented data investigating the immunological tumor microenvironment in patients with muscle-invasive bladder cancer treated with radical cystectomy, comparing those who had to activate FGFR-3 mutations versus wild-type cases. Analyses were performed comparing tumor mutational burden, neoantigen load, and immune checkpoint gene expression in both in a TCGA cohort (n=407) as well as an institutional cohort (n=199), between patients with and without activating FGFR-3 mutations.

Those with activating FGFR-3 mutations had less tumor mutational burden and neoantigen load; additionally, they had low expression of PD-1, PD-L1, and immune-related gene expression. These data suggest that combination therapies targeting FGFR3 and PD-1/PD-L1 may not be effective, although additional validation is required.


Abstract take-home message:

  • Patients with MIBC and activating FGFR-3 mutations were found to have less tumor mutational burden and neoantigen load; as well as low expression of PD-1, PD-L1, and immune-related gene expression

Presented by: Veronika Weyerer, MD, Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany;

Written by: Dr. Vikram M. Narayan (@VikramNarayan), Urologic Oncology Fellow with Ashish M. Kamat, MD (@UroDocAsh), Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX at the 17th meeting of the International Bladder Cancer Network, (IBCN, #IBCN2019) October 3rd – 5th, 2019 in Aarhus, Denmark.